Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1985 2
1986 2
1987 2
1988 7
1989 4
1990 3
1991 6
1992 6
1993 14
1994 3
1995 7
1996 4
1997 8
1998 2
1999 5
2000 14
2001 7
2002 6
2003 10
2004 6
2005 7
2006 7
2007 4
2008 10
2009 8
2010 6
2011 7
2012 5
2013 17
2014 21
2015 17
2016 22
2017 19
2018 50
2019 102
2020 98
2021 88
2022 72
2023 66
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

682 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effec …
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly pu …
Icosapent ethyl: scientific and legal controversies.
Curfman G, Shehada E. Curfman G, et al. Open Heart. 2021 Apr;8(1):e001616. doi: 10.1136/openhrt-2021-001616. Open Heart. 2021. PMID: 33888593 Free PMC article. Review.
Icosapent ethyl (Vascepa) is a purified preparation of the omega-3 fatty acid eicosapentaenoic acid, which is marketed by Amarin Pharma based in Ireland. ...Data supporting the efficacy of omega-3 fatty acids in the prevention of cardiovascular disease have been inc …
Icosapent ethyl (Vascepa) is a purified preparation of the omega-3 fatty acid eicosapentaenoic acid, which is marketed by Amar …
A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction.
Huston J, Schaffner H, Cox A, Sperry A, Mcgee S, Lor P, Langley L, Skrable B, Ashchi M, Bisharat M, Gore A, Jones T, Sutton D, Sheikh-Ali M, Berner J, Goldfaden R. Huston J, et al. Am J Cardiovasc Drugs. 2023 Jul;23(4):393-406. doi: 10.1007/s40256-023-00583-8. Epub 2023 May 15. Am J Cardiovasc Drugs. 2023. PMID: 37188993 Free PMC article. Review.
Icosapent ethyl (IPE) was the first fish oil product the US Food and Drug Administration (FDA) approved to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) in adults. ...
Icosapent ethyl (IPE) was the first fish oil product the US Food and Drug Administration (FDA) approved to reduce the risk of …
Icosapent Ethyl: Niche Drug or for the Masses?
Bazarbashi N, Miller M. Bazarbashi N, et al. Curr Cardiol Rep. 2020 Aug 8;22(10):104. doi: 10.1007/s11886-020-01356-4. Curr Cardiol Rep. 2020. PMID: 32770402 Review.
PURPOSE OF REVIEW: Despite achieving optimal levels of low-density lipoprotein cholesterol (LDL-C) with statins, the risk of atherosclerotic cardiovascular disease (ASCVD) persists. The purpose of this review is to outline the effects of icosapent ethyl (IPE), an ul …
PURPOSE OF REVIEW: Despite achieving optimal levels of low-density lipoprotein cholesterol (LDL-C) with statins, the risk of atherosclerotic …
Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides.
Pareek M, Mason RP, Bhatt DL. Pareek M, et al. Expert Opin Drug Saf. 2022 Jan;21(1):31-42. doi: 10.1080/14740338.2021.1954158. Epub 2021 Sep 7. Expert Opin Drug Saf. 2022. PMID: 34253137 Review.
We provide an overview of findings from recent meta-analyses, important observational studies, and a detailed description of landmark trials, including the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT). We further review reco …
We provide an overview of findings from recent meta-analyses, important observational studies, and a detailed description of landmark trials …
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1beta, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy.
Ridker PM, Rifai N, MacFadyen J, Glynn RJ, Jiao L, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Mason RP, Bhatt DL. Ridker PM, et al. Circulation. 2022 Aug 2;146(5):372-379. doi: 10.1161/CIRCULATIONAHA.122.059410. Epub 2022 Jun 28. Circulation. 2022. PMID: 35762321 Clinical Trial.
BACKGROUND: REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial) reported a 25% relative risk reduction in major adverse cardiovascular events with use of icosapent ethyl compared with pharmaceutical grade mineral oil. …
BACKGROUND: REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial) reported a 25% relative ris …
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ, Zamorano JL, Parhofer KG. Chapman MJ, et al. Pharmacol Ther. 2022 Sep;237:108172. doi: 10.1016/j.pharmthera.2022.108172. Epub 2022 Mar 15. Pharmacol Ther. 2022. PMID: 35304222 Free article. Review.
Emerging evidence from epidemiologic and genetic studies supports an independent causative role of triglycerides, triglyceride-rich lipoproteins, and their remnants in this pathology. Icosapent ethyl (IPE) is a highly purified, stable ethyl ester of eicosapentaenoic …
Emerging evidence from epidemiologic and genetic studies supports an independent causative role of triglycerides, triglyceride-rich lipoprot …
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, May HT, Shaikh K, Shekar C, Roy SK, Tayek J, Nelson JR. Budoff MJ, et al. Eur Heart J. 2020 Oct 21;41(40):3925-3932. doi: 10.1093/eurheartj/ehaa652. Eur Heart J. 2020. PMID: 32860032 Free PMC article. Clinical Trial.
AIMS: Despite the effects of statins in reducing cardiovascular events and slowing progression of coronary atherosclerosis, significant cardiovascular (CV) risk remains. Icosapent ethyl (IPE), a highly purified eicosapentaenoic acid ethyl est …
AIMS: Despite the effects of statins in reducing cardiovascular events and slowing progression of coronary atherosclerosis, significant card …
Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
Kim ES, McCormack PL. Kim ES, et al. Am J Cardiovasc Drugs. 2014 Dec;14(6):471-8. doi: 10.1007/s40256-014-0099-7. Am J Cardiovasc Drugs. 2014. PMID: 25428605 Review.
Icosapent ethyl (Vascepa) is a high-purity ethyl ester of eicosapentaenoic acid (EPA) that is de-esterified to EPA following oral administration. ...In a pivotal phase III trial, oral icosapent ethyl 4 g/day significantly decreased the placebo-correcte …
Icosapent ethyl (Vascepa) is a high-purity ethyl ester of eicosapentaenoic acid (EPA) that is de-esterified to EPA following o …
682 results

Searches related to "icosapent ethyl"